MALVERN, Pa., March 12, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum, or ...

DUBLIN, May 15, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that new and final updated data from its dedicated ventral curvature analysis of Peyronie's disease and XIAFLEX® ...

If approved, Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

Endo once again hit the vegetable aisle to illustrate the effects of Peyronie's disease. While the company has tapped various produce in the past as part of its unbranded campaign to bring awareness ...

DUBLIN, June 5, 2023 /PRNewswire/ -- Endo International plc (ENDPQ) announced today that post-hoc data from two Phase 3 studies of XIAFLEX ® (collagenase clostridium histolyticum, or CCH, injection ...

The 90-second commercial builds on the "Bent Carrot" campaign, launched in 2021, with creative that highlights a couple's journey from diagnosis to treatment. It spotlights the copay program designed ...

The drugmaker – which was known as Mallinckrodt beforemerging with Endo and rebranding as Keenova last year – said that ...

"These new results are consistent with earlier studies and reinforce that XIAFLEX (collagenase clostridium histolyticum) is both effective and well tolerated for men with Peyronie's disease, including ...

Hypersensitivity Reactions, Including Anaphylaxis: In the double-blind, placebo-controlled portions of the clinical trials in Peyronie's disease, a greater proportion of XIAFLEX-treated patients (4%) ...

MALVERN, Pa., Oct. 25, 2024 /PRNewswire/ -- Endo, Inc. announced today that a post hoc data analysis of a Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum, or CCH) in patients ...